Denosumab: Prolia®; Jubbonti®; Xgeva®; Wyost®
Patients should be encouraged to continue denosumab therapy long term. If discontinuation does occur, appropriate steps must be taken to prevent the rapid bone.
Denosumab: A novel antiresorptive drug for osteoporosisWhere treatment for osteoporosis is required beyond 5 years of bisphosphonate therapy, options other than bisphosphonates, such as denosumab, may be considered, ... denosumab (Prolia) - Blue Shield of CaliforniaRare side effects and risks related to the drug, such as osteonecrosis of the jaw (ONJ), atypical femoral fractures (AFF), and rebound effect should always be. Cancel the denosumab holiday - Miller Bone CenterProlia (denosumab) is administered by a healthcare professional subcutaneously every six months and is managed through the medical benefit and ...
Autres Cours:
